Prosecution Insights
Last updated: November 12, 2026
Application No. 18/276,852

EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 4a

Final Rejection §112
Filed
Aug 10, 2023
Priority
Feb 15, 2021 — DK PA 2021 70066 +1 more
Examiner
CORNELIUS, CLAIRE ADRIENNE
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hvidovre Hospital
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
5 granted / 7 resolved
+11.4% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
34 currently pending
Career history
40
Total Applications
across all art units

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election/Restrictions Applicant’s election without traverse of four species in the reply filed on 02/19/2026 is acknowledged. For claims 1, 30, and 42, Applicant elects SEQ ID NO: 1. For claims 1 and 42, Applicant elects the additional adaptive mutation Q2931R according to SEQ ID NO: 1. For claim 28, Applicant elects SEQ ID NO: 10. For claims 31 and 32, Applicant elects SEQ ID NO: 7. Claims 27, 29 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 02/19/2026. Claims 1, 26, 28, 30-42 are under consideration. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statement (IDS) submitted on 11/15/2023 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Nucleotide and/or Amino Acid Sequence Disclosures REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES Items 1) and 2) provide general guidance related to requirements for sequence disclosures. 37 CFR 1.821(c) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.821(a) must contain a "Sequence Listing," as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.821 - 1.825. This "Sequence Listing" part of the disclosure may be submitted: In accordance with 37 CFR 1.821(c)(1) via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter "Legal Framework") as an ASCII text file, together with an incorporation-by-reference of the material in the ASCII text file in a separate paragraph of the specification as required by 37 CFR 1.823(b)(1) identifying: the name of the ASCII text file; ii) the date of creation; and iii) the size of the ASCII text file in bytes; In accordance with 37 CFR 1.821(c)(1) on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation-by-reference of the material in the ASCII text file according to 37 CFR 1.52(e)(8) and 37 CFR 1.823(b)(1) in a separate paragraph of the specification identifying: the name of the ASCII text file; the date of creation; and the size of the ASCII text file in bytes; In accordance with 37 CFR 1.821(c)(2) via the USPTO patent electronic filing system as a PDF file (not recommended); or In accordance with 37 CFR 1.821(c)(3) on physical sheets of paper (not recommended). When a “Sequence Listing” has been submitted as a PDF file as in 1(c) above (37 CFR 1.821(c)(2)) or on physical sheets of paper as in 1(d) above (37 CFR 1.821(c)(3)), 37 CFR 1.821(e)(1) requires a computer readable form (CRF) of the “Sequence Listing” in accordance with the requirements of 37 CFR 1.824. If the "Sequence Listing" required by 37 CFR 1.821(c) is filed via the USPTO patent electronic filing system as a PDF, then 37 CFR 1.821(e)(1)(ii) or 1.821(e)(2)(ii) requires submission of a statement that the "Sequence Listing" content of the PDF copy and the CRF copy (the ASCII text file copy) are identical. If the "Sequence Listing" required by 37 CFR 1.821(c) is filed on paper or read-only optical disc, then 37 CFR 1.821(e)(1)(ii) or 1.821(e)(2)(ii) requires submission of a statement that the "Sequence Listing" content of the paper or read-only optical disc copy and the CRF are identical. Specific deficiencies and the required response to this Office Action are as follows: Specific deficiency – Nucleotide and/or amino acid sequences appearing in the drawings, Figures 8B, 1-2 are not identified by sequence identifiers in accordance with 37 CFR 1.821(d). Sequence identifiers for nucleotide and/or amino acid sequences must appear either in the drawings or in the Brief Description of the Drawings. Required response – Applicant must provide: Replacement and annotated drawings in accordance with 37 CFR 1.121(d) inserting the required sequence identifiers; AND/OR A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3) and 1.125 inserting the required sequence identifiers into the Brief Description of the Drawings, consisting of: A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version); A copy of the amended specification without markings (clean version); and A statement that the substitute specification contains no new matter. Specification The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code on page 19. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. Claim Objections Claims 1, 33, and 42 are objected to because of the following informalities: Claims 1 and 42: Change “wherein the said molecule” to “wherein said molecule”. Change “hereof” to “thereof”. Claim 33: Change “said molecule” to “said nucleic acid molecule” for consistency with other claims. Change (focus forming units)/ml to (focus forming units/ml). Claim 42: The lettering, for example, d) and e), is incorrect for the “additional adaptive mutations” . To retain the existing a) and b) hierarchy for “culturing a cell…” and “detecting the replicating RNA…”, respectively, use (i), (ii) or (iii) for the additional adaptive mutations in order to break it into three groups similar to claim 1 (even though, note, in claim 1, a), b) and c) are used). Appropriate correction is required. Applicant is advised that should claims 34-35 be found allowable, claims 38-41 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 26, 28, 30-42 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. See claims 1, 26, 28, 30-42 as submitted 12/19/2023. Claims 1 and 42: It is unclear if the desired amino acid sequence is at least 99% identical to that of SEQ ID NO: 1 (or fragments) and then also has the addition of adaptive mutations or at least 99% to that of SEQ ID NO: 1 (or fragment) already with the adaptive mutations. Alternatively, it is also unclear if the 99% identity is to SEQ ID NO: 1 and to any fragment between amino acids 1027-3008 of SEQ ID NO: 1 or 99% identity to amino acids 1027-3008 of SEQ ID NO: 1. Additionally, for both claims 1 and 42, it is unclear if genotype 4a strain ED43 apply to both the virus and the replication system. Furthermore, the terminology – “replication system” and its meaning are unclear. Claims 1 and 42 recite “or a fragment hereof encoding the said HCV replication system corresponding to NS3-NS5B between amino acids 1027-3008 of SEQ ID NO: 1” and it is unclear which amino acids between 1027-3008 of SEQ ID NO: 1 actually correspond to the NS3-NS5B. Additionally, it is unclear as written if “optionally” applies only to the adaptive mutation T827A according to SEQ ID NO: 1 or also is extended to the additional adaptive mutation a) Q2931R. Claim 26 recites a further nucleotide adaptive mutation in the 5’ UTR region (G38A). There are three different options given in claim 1 and without a reference polynucleotide sequence from claim 1, it is difficult to decipher the relationship/correspondence between the claims 1 and 26. Claim 30 recites “between amino acids 810-3008 of SEQ ID NO: 1”. It is unclear which amino acids between 810-3008 of SEQ ID NO: 1 actually correspond to NS2-NS5B. Claims 31-32 recite “between nucleic acids”. It is unclear if “nucleic acids” should actually be “nucleotides”. It is also unclear which nucleotides correspond to the 5’UTR (claim 31) and 3’UTR (claim 32). And finally, without a reference polynucleotide sequence from claim 1, it is difficult to decipher the relationship/correspondence between claims 1 and 31-32. Claim 36 recites an immunogenic composition comprising hepatitis C virus particle produced by the method of claim 34 or an immunogenic part thereof. It is not clear if the immunogenic part referred to is the HCV replication system (as recited in claim 34) or something else. Claim 41 recites a method for producing a hepatitis C virus replication system, comprising culturing a cell according to claim 38. Claim 38 is a method claim, not a product claim to the cell and even as a method claim, it does not address “culturing a cell”. As a result there appears to be a lack of antecedent basis for this claim. Claim 42 recites a method for screening an anti-hepatitis C virus substance but does not include a step with a description for how the anti-hepatitis C virus substance and presumably the hepatitis C virus particle interact in order to detect the replicating RNA or virus particles. The specification, however, states on pages 34-35, “b) subjecting said virus infected cell to the anti-hepatitis C virus substance”. To remedy, include this intermediate step from the specification within the claim, if still appropriate. Additionally, the language, “anti-hepatitis C virus substance” is problematic as the metes or bounds of “substance” are unclear. Allowable Subject Matter Claim 28 with election of strain ED43-20m (SEQ ID NO: 10) only is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Regarding claim 30, Gottwein et al. (Gottwein) (WO2011038737-A1)(See PTO-892 Notice of References Cited) teaches SEQ ID NO: 2 with a 100% match to that of the amino acids 810-3008 of SEQ ID NO: 1 in the instant application (See Result 1, AZG45096, us-18-276-852-1_copy_810_3008.minpct99.rag, 03/19/2026, in supplemental contents tab). Alternatively, depending on interpretation, Gottwein’s teaching of SEQ ID NO: 2 (above) has a 99.3% match to the amino acids 810-3008 of SEQ ID NO: 1 with the specific adaptive mutations recited in claim 1 included (See Result 4, AZG45096, us-18-276-852-1substitutions-copy-810-3008.minpct99.rag, 03/20/2026, in supplemental contents tab). However, while SEQ ID NO: 2 as taught by Gottwein has a 99.3% match, the SEQ ID NO: 2 sequence does not include any of the specific adaptive mutations recited in claim 1. No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire Cornelius whose telephone number is (571) 272-0860. The examiner can normally be reached M-F, 0930-1700. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas J. Visone can be reached at (571) 270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.C./Examiner, Art Unit 1672 /M FRANCO G SALVOZA/Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Aug 10, 2023
Application Filed
May 04, 2026
Non-Final Rejection mailed — §112
Aug 03, 2026
Response Filed
Nov 03, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12752003
LIPIDATED FLIPR AND USES THEREOF IN VACCINE
3y 2m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.0%)
Moderate
PTA Risk
Based on 7 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month